TCM
Tang Capital Management Portfolio holdings
AUM
$1.98B
This Quarter Return
+16.47%
1 Year Return
+21.62%
3 Year Return
+290.69%
5 Year Return
+284.46%
10 Year Return
+928.34%
AUM
$1.4B
AUM Growth
+$1.4B
(+43%)
Cap. Flow
+$313M
Cap. Flow
% of AUM
22.32%
Top 10 Holdings %
Top 10 Hldgs %
35.88%
Holding
163
New
35
Increased
43
Reduced
14
Closed
8
Top Buys
| 1 |
Aurinia Pharmaceuticals
AUPH
|
$32.6M |
| 2 |
BioNTech
BNTX
|
$32.1M |
| 3 |
Relay Therapeutics
RLAY
|
$25.3M |
| 4 |
iTeos Therapeutics
ITOS
|
$24.6M |
| 5 |
Immunocore
IMCR
|
$21.8M |
Top Sells
| 1 |
Eli Lilly
LLY
|
$24.4M |
| 2 |
Dynavax Technologies
DVAX
|
$6.68M |
| 3 |
Beam Therapeutics
BEAM
|
$2.45M |
| 4 |
Inhibrx
INBX
|
$2.37M |
| 5 |
CRISPR Therapeutics
CRSP
|
$2.35M |
Sector Composition
| 1 | Healthcare | 95.59% |
| 2 | Technology | 1.47% |
| 3 | Communication Services | 1.22% |
| 4 | Real Estate | 0.34% |
| 5 | Financials | 0.3% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Evolus
EOLS
$494M
| $78.5M | 5.61% | 4,847,399 | – | – |
|
2
Tarsus Pharmaceuticals
TARS
$2.47B
| $74.2M | 5.3% | 2,254,797 | – | – |
|
|
3
Aurinia Pharmaceuticals
AUPH
$1.58B
| $53M | 3.79% | 7,229,500 +4,450,000 | +160% | +$32.6M |
|
4
Viridian Therapeutics
VRDN
$1.5B
| $51M | 3.65% | 2,242,925 +850,000 | +61% | +$19.3M |
|
5
Mirum Pharmaceuticals
MIRM
$3.71B
| $50.2M | 3.59% | 1,287,107 | – | – |
|
6
KalVista Pharmaceuticals
KALV
$678M
| $50M | 3.57% | 4,321,547 +102,718 | +2% | +$1.19M |
|
7
AnaptysBio
ANAB
$569M
| $44.6M | 3.18% | 1,330,879 | – | – |
|
|
8
Immunocore
IMCR
$1.62B
| $34.4M | 2.46% | 1,105,600 +700,000 | +173% | +$21.8M |
|
9
Vaxcyte
PCVX
$4B
| $34.3M | 2.45% | 300,000 | – | – |
|
|
10
BioNTech
BNTX
$24B
| $32.1M | 2.29% | +270,000 | New | +$32.1M |
|
11
ANI Pharmaceuticals
ANIP
$2.03B
| $26.8M | 1.92% | 450,000 | – | – |
|
12
PTC Therapeutics
PTCT
$3.92B
| $26M | 1.86% | 700,000 | – | – |
|
|
13
Relay Therapeutics
RLAY
$619M
| $25.3M | 1.8% | +3,568,058 | New | +$25.3M |
|
|
14
iTeos Therapeutics
ITOS
| $24.6M | 1.76% | +2,407,800 | New | +$24.6M |
|
15
Applied Therapeutics
APLT
$71M
| $23.2M | 1.66% | 2,730,000 +400,000 | +17% | +$3.4M |
|
16
Acadia Pharmaceuticals
ACAD
$4.38B
| $23.1M | 1.65% | 1,500,000 | – | – |
|
|
ITCI
17
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $22M | 1.57% | 300,000 | – | – |
|
|
18
Dynavax Technologies
DVAX
$1.19B
| $21.2M | 1.51% | 1,900,000 -600,000 | -24% | -$6.68M |
|
19
Galapagos
GLPG
$2.07B
| $20.2M | 1.44% | 700,000 +644,391 | +1,159% | +$18.6M |
|
20
GSK
GSK
$79.9B
| $18.4M | 1.31% | 450,000 +50,000 | +13% | +$2.04M |
|
|
LENZ
21
LENZ Therapeutics
LENZ
$1.1B
| $18.2M | 1.3% | 766,940 +19,324 | +3% | +$459K |
|
22
NVIDIA
NVDA
$4.24T
| $17.9M | 1.28% | 147,732 +32,713 | +28% | +$3.97M |
|
23
Neurocrine Biosciences
NBIX
$13.8B
| $17.3M | 1.23% | +150,000 | New | +$17.3M |
|
24
Altimmune
ALT
$338M
| $16.9M | 1.21% | 2,750,000 | – | – |
|
|
AVDL
25
Avadel Pharmaceuticals
AVDL
$1.43B
| $16.1M | 1.15% | 1,230,000 | – | – |
|